[ad_1]
British regulatory authorities have issued an indication to hospitals that people with severe allergies should not receive the Pfizer / BioNTech vaccine against Covid-19. The warning came after two British National Health Service officials had allergic reactions after receiving the vaccine.
The UK was the first country to start administering the Pfizer / BioNTech vaccine on Tuesday, having started the process with the elderly and healthcare professionals who are among the priority groups. It was in two healthcare professionals that they were found to trigger symptoms of “anaphylactic reaction” shortly after receiving the vaccine. According to Sky News, both are already on the mend and both have a history of severe allergies, to the point of having to carry the adrenaline pen for SOS situations.
In these two cases, the Regulatory Agency for Medicines and Health Products (MHRA) issued a preventive alert so that the vaccine is not administered to anyone who has a history of serious allergies, whether they are allergies to drugs or food products.
According to Sky News, the British SNS has already announced that all entities involved in the vaccination program have been informed of this situation and, as of Wednesday, all patients who are going to receive the Pfizer vaccine will be previously questioned if have a history of allergic reactions.
A Pfizer spokesperson has already responded to the cases, stating that no allergy-related problems were detected in clinical trials, but as a preventive measure, the pharmacist supports the regulator’s decision to suspend vaccination in this age group with a history of allergies. serious.
“The health regulator informed us of two reports associated with an allergic reaction to the vaccine. As a preventive measure, the MHRA issued temporary guidelines for the National Health Service to “stop vaccinating these people, until an investigation into the causes of the allergic reaction is completed. Research Supporting Pharmaceutical Company: “Pfizer and BioNTech are Supporting MHRA Research.”
“In phase three of the clinical trials, the vaccine was generally positively tolerated, with no safety concerns detected by the independent committee that analyzed the data,” says Pfizer in a statement, recalling that the trial phase involved 44,000 participants and more. . 42 thousand have already received the second dose.
[ad_2]
